GVK BIO
Robert R. Ruffolo is a distinguished scientist with a number of global recognitions for his executive leadership in the Pharmaceutical industry. He was appointed to the Board of Directors of GVK BIO in April 2019.
Dr. Ruffolo holds a B.S. degree in Pharmacy, and a Ph.D. degree in Pharmacology, both from The Ohio State University.
He served as the President of R&D and Senior Vice President of Wyeth Pharmaceuticals (now, Pfizer) from 2002 to 2008. Prior to Wyeth, Dr. Ruffolo was the Senior Vice President in R&D at SmithKline Beecham Pharmaceuticals (now GSK) for 17 years. He played a significant role in the discovery and development of a number of marketed products, including Carvedilol, Ropinirole, Dobutamine and Eprosartan, among others. He has been recognized with several prestigious awards, including the Discoverer’s Award in 2008 for his pioneering work on the discovery of Carvedilol for the treatment of congestive heart failure. Dr.Ruffolo currently serves as a Director at Sigilon Therapeutics, Elucida Oncology, Sapience Therapeutics and Aridis Pharmaceuticals. He is also the President of Ruffolo Consulting LLC, a position he has held since 2008.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
GVK BIO
1 followers
GVK BIO, a leading Contract Research & Development (R&D) Organization that services the global Biopharma industry; is headquartered in Hyderabad, India with operations in seven sites including California, USA. Established in 2001, GVK BIO has over 19 years of rich experience across the Research and Development value chain with a focus on speed and quality.